近日，工业和信息化部等七部门印发《关于推动脑机接口产业创新发展的实施意见》，提出，到2027 年，脑机接口关键技术取得突破，初步建立先进的技术体系、产业体系和标准体系。电极、芯片和整机 产品性能达到国际先进水平，脑机接口产品在工业制造、医疗健康、生活消费等加快应用。产业规模不 断壮大，打造2至3个产业发展集聚区，开拓一批新场景、新模式、新业态。到2030年，脑机接口产业创 新能力显著提升，形成安全可靠的产业体系，培育2至3家有全球影响力的领军企业和一批专精特新中小 企业，构建具有国际竞争力的产业生态，综合实力迈入世界前列。 国元证券指出，脑机接口通过在脑与机器之间建立信息通道，实现生物智能与机器智能的协同交互，是 生命科学和信息科学融合发展的前沿技术。当前，脑机接口创新成果持续涌现，产业加速壮大，正孕育 颠覆性突破，已成为科技创新和产业创新深度融合的重要领域。随着脑机接口技术加速发展，产业政策 日趋明晰，已有北京、上海、南京、四川、山东等省区市发布了相关政策，同时一些医疗机构、企业也 加速推进脑机接口的创新技术研发，产业链中上游的技术进步带来下游应用端不断突破，国内脑机接口 公司有望逐步实现商业化应用，并向产 ...

Group 1: Financial Sector Performance - Broker stocks collectively surged at the market open, with Guosheng Financial hitting the daily limit, and several other firms like Huijin Co., Hato Technology, and Tianli Technology rising over 5% [1] - Bank stocks were active, with Agricultural Bank of China rising over 1% to set a new historical high, while other banks like Everbright Bank and Postal Savings Bank also saw gains [3] - The total margin financing balance across both exchanges exceeded 2 trillion yuan for the first time in ten years, reaching 20,056.89 billion yuan, an increase of 167.36 billion yuan from the previous trading day [3] Group 2: Brain-Computer Interface Sector - The brain-computer interface concept saw significant movement, with Qisheng Technology hitting the daily limit and other companies like Weisi Medical and Sanbo Neuroscience also experiencing gains [8] - A new policy from multiple government departments aims to promote the high-quality development of the brain-computer interface industry, targeting breakthroughs in key technologies by 2027 and establishing advanced technical and industrial systems [10] Group 3: Medical Device Sector - The medical device sector experienced a short-term surge, with companies like Sanxin Medical hitting the daily limit and Sino Medical rising over 10% [10] - Recent government policies indicate a shift towards supporting innovative medical devices, suggesting potential recovery in valuations and performance for the medical device sector [10] Group 4: Poultry Industry - The poultry sector saw gains, with Xiaoming Co. rising over 10% and other companies like Minhe Co. and Yisheng Co. also increasing in value [10] - Industry insiders noted a rebound in chicken market demand and a decrease in breeding costs as key factors driving stock price increases [10] Group 5: Dairy Industry in Hong Kong - Dairy stocks in Hong Kong strengthened, with Aoyuan Group rising over 30% and other companies like China Shengmu and Modern Farming also seeing significant increases [12] - Analysts highlighted a strategic shift in China's dairy industry from "scale expansion" to "value enhancement," with solid dairy products like cheese and butter becoming increasingly important [12] Group 6: Crystal Technology Holdings - Crystal Technology Holdings saw a nearly 6% increase, with expectations of achieving a profit of at least 50 million yuan in the first half of 2025, a significant turnaround from a loss of 1.238 billion yuan in the same period of 2024 [12] - The anticipated improvement in performance is attributed to a partnership with DoveTree Medicines, leveraging AI and robotics for drug discovery solutions [12]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by recent policy support and technological advancements, with several companies in the field seeing substantial stock price increases. Group 1: Company Performance - QiSheng Technology (麒盛科技) saw its stock price rise by 10.01% to 14.40, with a market capitalization of 5.08 billion, focusing on sleep-related technologies and brain-machine interaction [2] - Innovation Medical (创新医疗) increased by 9.99% to 20.59, with a market cap of 8.57 billion, holding a 40% stake in BoLing Brain-Machine Technology, which is developing core BCI technologies [2] - Xiangyu Medical (翔宇医疗) surged by 13.72% to 65.97, with a market cap of 10.56 billion, having completed several key projects in the BCI field and holding numerous patents [2] - Chengpin Technology (诚品通) rose by 8.60% to 23.23, with a market cap of 6.04 billion, collaborating with Tsinghua University on both non-invasive and invasive BCI technologies [2] Group 2: Industry Developments - On August 7, the Ministry of Industry and Information Technology and six other departments released guidelines to promote BCI innovation, aiming for breakthroughs in key technologies by 2027 [3] - The establishment of the Hubei BCI Industry Innovation Development Alliance was announced on August 9, indicating a collaborative effort to advance the sector [3] - The 2025 World Robot Competition showcased non-invasive BCI products for nerve injury treatment, highlighting the practical applications of BCI technology [3] Group 3: Institutional Insights - The guidelines emphasize the establishment of an advanced technology, industry, and standard system for BCI by 2027, with expectations for BCI applications in healthcare, rehabilitation, and skill replacement [4] - BCI technology is positioned at the intersection of life sciences and information sciences, facilitating collaboration between biological and machine intelligence [4] - Various provinces and cities in China are implementing policies to support BCI development, with significant potential for commercialization in healthcare and other sectors [5]

8月12日，A股脑机接口概念板块走高，其中截至发稿，麦澜德股价涨超18%，翔宇医疗涨12%，麒盛科技涨10%。另外，创新医疗、诚益通、倍益康等多只 概念股走高。 | | 脑机接口 | | | | --- | --- | --- | --- | | | 1648.57 3.24% | | | | 基金 成分股 | 资金 板块分析 | 新闻 | 简况(F1 | | 人气龙头 | | | | | 1 创新医疗 | 2 际华集团 | | 3 翔宇医疗 | | 9.99% | -3.37% | | 12.05% | | 首板涨停 领涨15次 | 4天2板 领涨5次 | | 领涨5次 | | ●展开分析 | 最新 | 涨幅 + | 流通市值 | | 麦澜德 | 53.01 | 18.46% | 19.5亿 | | ■ 688273 | | | | | 首板涨停 最终涨停 10:14 | | | | | 翔宇医疗 | 65.00 | 12.05% | 104亿 | | 麗 688626 | | | | | 人气龙头3 | | | | | 麒盛科技 | 14.40 | 10.01% | 50.8亿 | | 603610 | ...

Group 1 - The core viewpoint of the article highlights the significant rise in Hong Kong's brain-computer interface (BCI) concept stocks, driven by a recent policy initiative from multiple government departments aimed at promoting the BCI industry [1] - The Ministry of Industry and Information Technology, National Development and Reform Commission, and Ministry of Education, among others, jointly issued implementation opinions on August 7, targeting breakthroughs in key technologies by 2027 and the establishment of a technology, industry, and standards system [1] - By 2030, the goal is to cultivate 2-3 global leading enterprises in the BCI sector, indicating a strategic push for China to gain a competitive edge in the global BCI landscape [1] Group 2 - Recent breakthroughs in policy, technology, capital, and medical applications signify that BCI technology is transitioning from laboratory research to large-scale commercial use [1] - According to Guojin Securities, the BCI sector has diverse application scenarios and rich product and research paths, suggesting a vast potential market that could accelerate commercialization with supportive policies for product registration and medical insurance [1] - Domestic leading companies have made significant technological advancements in non-invasive BCI products, indicating a promising commercial potential for these innovations [1] Group 3 - Notable stock performances include Nanjing Panda Electronics rising over 10%, Brain Hole Technology increasing by 7%, and MicroBrain Science up by 5%, reflecting investor optimism in the BCI sector [1] - The stock prices and percentage changes of key companies are as follows: Nanjing Panda Electronics at 5.880 with a 10.11% increase, Brain Hole Technology at 0.230 with a 6.98% increase, MicroBrain Science at 16.020 with a 4.98% increase, and Brain Motion Aurora-B at 5.150 with a 1.58% increase [1]

Group 1 - The core viewpoint of the article highlights the recent surge in brain-computer interface (BCI) concept stocks, with companies like Innovation Medical experiencing significant gains, including three consecutive trading limits in six days [1] - The Ministry of Industry and Information Technology, along with six other departments, has released an implementation opinion aimed at promoting innovation and development in the BCI industry [1] - The document outlines a goal for 2027, where key technologies in the BCI field are expected to achieve breakthroughs, leading to the establishment of an advanced technical system, industrial system, and standard system [1] Group 2 - Notable stock performances include Qi Sheng Technology reaching a trading limit, Bei Yi Kang increasing over 10%, and other companies like Cheng Yi Tong, Sanbo Neuroscience, Aipeng Medical, Nanjing Panda, and Jiahe Intelligent also experiencing upward trends [1] - The overall market sentiment is positively influenced by the government's supportive policies and the anticipated growth in the BCI sector [1]

诚益通（300430.SZ）8月12日在投资者互动平台表示，公司已确立"侵入式与非侵入式"双轨并行的战略 布局，在非侵入式严肃医疗赛道，公司目前主要将现有康复设备与脑机接口进行结合，升级现有产品功 能，并积极推进相关商业化落地；除医疗领域外，公司也在积极探索"非医疗"场景的应用，包括教育、 养老、健康等多个领域，其中，在教育领域，公司已推出面向专注力检测与训练的脑机接口生物反馈系 统。在侵入式领域，公司脑机接口技术研究验证中心与动物实验中心正在建设中，作为公司在脑机接口 领域的重要战略布局，两大中心将构建"基础研究-技术验证-成果转化"的完整创新链条。 每经AI快讯，有投资者在投资者互动平台提问：请问公司下属脑连科技的bci脑控机器人相关开发进度 如何？有哪些储备技术和产品？ （文章来源：每日经济新闻） ...

本轮所募资金将主要用于加速推进新一代技术研发及开展大规模临床试验。自2022年成立以来，智冉医 疗发展迅猛，已融资总额近5亿元人民币。 投资界8月12日消息，近日，专注于研发新一代侵入式柔性脑机接口平台北京智冉医疗科技有限公司 （简称：智冉医疗），宣布完成超3亿元A轮融资，本轮融资由社保基金中关村自主创新专项基金（君 联资本担任管理人）、君联资本、IDG资本联合领投，老股东元生创投持续大额加注，国寿资本、北京 市医药健康产业投资基金、联想创投及老股东美团龙珠、BV百度风投跟投。 智冉医疗由方英博士和宋麒博士共同创立。方英博士为北京脑科学与类脑研究所研究员/博导、科技部 脑专项"神经记录与调控新技术平台"牵头人，长期从事柔性高通量电极与神经记录调控研究。宋麒博士 毕业于爱荷华大学电子计算机工程专业，连续创业，曾任国内 AI 医疗头部企业创始人、CEO，主导国 内首张AI医疗三类证的临床转化与注册工作。 君联资本董事总经理周瑔表示："脑机接口正经历从实验室到产业化的关键跃迁，是高精度、高集成 度、高壁垒的平台型技术，面向多个下游应用领域，蕴含着巨大的商业潜力和社会价值。随着新材料、 半导体、人工智能等众多基础产业 ...

Company Overview - Zhiruan Medical has completed over 300 million yuan in Series A financing, led by the Social Security Fund Zhongguancun Independent Innovation Special Fund, Junlian Capital, and IDG Capital, with continued investment from existing shareholders [1] - Since its establishment in 2022, the company has raised nearly 500 million yuan in total funding, which will primarily be used for the development of new technologies and large-scale clinical trials [1] Technology and Innovation - Zhiruan Medical focuses on invasive brain-computer interface (BCI) technology, which involves implanting electrodes directly into the brain to collect high-resolution neural signals and achieve precise neuron modulation [2] - The company has developed high-throughput flexible electrodes that have received patent authorization in both China and the United States, allowing for efficient neural signal collection and reduced immune response [2][3] - A fully implanted high-throughput wireless signal acquisition system has been created, capable of precise collection of neural action potentials from up to 1024 channels, with a significant reduction in power consumption [3] Research and Development - The company has established a high-precision brain data platform with over 20TB of animal neural data and 6TB of human deep brain data, which aids in training neural models and improving decoding performance [3] - Zhiruan Medical has developed a multi-degree-of-freedom implantation robot that allows for micron-level positioning accuracy, enhancing the efficiency and safety of electrode implantation [3] Industry Context - The global BCI industry is entering a rapid growth phase, with companies like Neuralink making progress in human clinical trials [4] - The shift from rigid to flexible electrodes is seen as crucial for improving signal quality and stability, as well as reducing immune response risks, which are key factors for clinical application [4] - Invasive BCI technology is expected to achieve breakthroughs in treating conditions such as spinal cord injuries, ALS, and depression [4]

Investment Rating - The report maintains a "Positive" investment rating for the software and services industry [8]. Core Insights - The report emphasizes the ongoing trend of accelerated monetization of AI applications, despite short-term market fluctuations. The recent release of OpenAI's GPT-5 is expected to enhance commercial viability and drive growth in related sectors [7][50][54]. Summary by Sections Market Performance - Last week, the computer sector experienced a slight decline of 0.41%, ranking 31st among major industries, with a trading volume accounting for 9.22% of the total market [2][5][16]. Key Developments - The Ministry of Industry and Information Technology, along with six other departments, issued guidelines to promote innovation in the brain-computer interface industry, setting clear development goals for 2027 and 2030 [22][23]. - China successfully launched a group of low-orbit satellites for satellite internet, marking a significant step in the country's satellite industry [28][32]. - The 2025 World Robot Conference opened in Beijing, focusing on advancements in robotics technology and applications [39][44]. Investment Recommendations - The report suggests focusing on: 1. AI infrastructure 2. Overseas applications in video, coding, and integrated solutions in AI+ fields 3. Vertical integration companies in closed-loop scenarios such as education, taxation, and healthcare [7][50][54]. AI Application Insights - The release of GPT-5 is noted for its improved performance and cost efficiency, which may accelerate the commercialization of AI applications. The annual recurring revenue (ARR) for OpenAI is projected to reach $200 billion by the end of the year, reflecting a significant growth trajectory [59][60].